Phase 2 N=22 Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 77.3 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent High Grade B-Cell Lymphoma
Primary: Incidence of Any Grade Cytokine Release Syndrome (CRS) — 10; 9 Participants
Phase 2 N=64 Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Hematopoietic Cell Transplantation Recipient · Plasma Cell Myeloma
Primary: Progression-free Survival — 73.3 Months
Phase 2 N=21 Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
PTSD
Primary: Change in CAPS-5 Total Severity Score — -13.95 score on a scale
Phase 2 N=158 Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Percentage of Participants With Adequate Estrogen Suppression After 8 Weeks of Adjuvant Anastrozole 10 mg Daily — 76.0 percentage of participants
Phase 2 N=104 A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD)
Primary: Change From Baseline to Week 12 in the Adaptive Behavior Composite (ABC) Score of the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) — 3.250; 2.819; 2.807…
Phase 2 N=28 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Bladder Cancer
Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants
Phase 2 N=179 Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
Prostate Cancer
Primary: Time to Treatment Failure (TTF) — 5.5; 5.7 Months
Phase 2 N=143 Evaluate Safety, Efficacy and Pharmacokinetics
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
Phase 2 N=190 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology — 51.84; 63.13; 73.92; 12.62 Percentage…
Phase 2 N=48 Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
Metastatic Non Small Cell Lung Cancer
Primary: Immune Related Progression Free Survival (irPFS) at 1 Year — 16 Participants
Phase 2 N=135 A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
HER2-negative Breast Cancer
Primary: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) — -62.7; -62.8; -67.1; -66.9…
Phase 2 N=26 Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
Metastasis From Malignant Tumor of Prostate (Disorder)
Primary: Region-Level Correct Localization Rate (CLR) — 86.67; 86.67; 76.67; 80.00 percentage of Regions
Phase 2 N=64 A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
Mild Cognitive Impairment · Dementia
Primary: Treatment-emergent Adverse Events — 19; 20 Participants
Phase 2 N=94 SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
MDS · CMML · AML
Primary: Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation — -16.143…